Genome-Wide Analysis of 1.2 Million People Uncovers 343 Risk Loci for Chronic Pain
Researchers pooled genetic data from over 1.2 million individuals to identify 343 independent genome sites associated with multidimensional chronic pain. The findings highlight 92 novel genetic associations and reveal causal links between pain variants, substance use disorders, and inflammation markers.
By Sofia Matos
Share this story
A massive genetic analysis of more than 1.2 million people has mapped 343 distinct regions of the human genome linked to chronic pain. The study, published November 12 in Nature Neuroscience, pooled DNA and health records from three major biobanks to untangle the biological roots of a condition that currently lacks objective clinical indicators.[1][2]
The findings significantly expand the known genetic architecture of pain and provide a rigorous foundation for future biomarker development. Chronic pain affects roughly one-fifth of the global population, imposing a massive personal and economic toll while remaining notoriously difficult to treat.[1]
"Despite its growing public health impact, there are no clinically useful objective indicators of chronic pain that could enhance preventive and therapeutic interventions to address it," the research team wrote in the study. This diagnostic gap has historically hindered the development of targeted, non-addictive therapies.[1]
Without objective biological tests, clinicians rely entirely on self-reported symptoms to guide therapeutic interventions. This leaves many patients with only partial relief and contributes heavily to the widespread misuse of opioid medications, driving the search for precise genetic targets.[1]
To overcome the statistical limitations of smaller, localized studies, a research team led by Sylvanus Toikumo and Henry R. Kranzler at the Crescenz VA Medical Center and the University of Pennsylvania turned to massive genomic databases. They aggregated genetic and phenotypic data from 1,235,695 individuals of European ancestry.[1][3]
The dataset combined the Million Veteran Program, the UK Biobank, and FinnGen, creating one of the largest genome-wide association studies ever conducted on human pain. The Million Veteran Program provided the largest single cohort, bringing extensive longitudinal health records from former military personnel.[1]
The UK Biobank and FinnGen supplemented this with deep, population-level genetic and phenotypic data from the United Kingdom and Finland, creating a robust, cross-national dataset. Because each of the three biobanks measures pain using entirely different methodologies, the researchers had to harmonize the data before they could analyze it.[1]
The Million Veteran Program tracks self-reported pain intensity over a period of several years, while the UK Biobank counts the specific number of painful body sites a patient reports. FinnGen, the third repository, relies strictly on clinical diagnosis codes.[1]
The team combined these disparate metrics into a single, unified phenotype they termed multidimensional pain. This harmonization allowed them to run a highly powered meta-analysis across the entire cohort, extracting signals that would have been invisible in smaller, isolated datasets.[1][2]
Mapping the Genetic Architecture
The genome-wide association study identified 343 independent genetic loci strongly associated with this multidimensional pain metric. Of those sites, 92 had never been linked to pain in any previous genomic scans, which had collectively reported just over 170 loci in total prior to this November 2026 publication.[1][2]
This massive expansion provides a much higher-resolution map of where chronic pain originates in the human genome, moving the field closer to a comprehensive understanding of its biological basis. Identifying a broad genomic region is only the first step; researchers must then determine which specific genes within that region actually drive the physiological effect.[1]
Drawing on multi-omic data and precise measurements of gene regulation, the team prioritized 490 specific genes that appear to directly influence pain. By mapping these genes to their corresponding proteins, researchers can begin to identify which molecular pathways are malfunctioning in chronic pain patients.[1]
These 490 genes exert their effects primarily through regulatory mechanisms in brain and blood tissue, highlighting the systemic nature of chronic pain syndromes. The genetic risk was predominantly enriched in central glutamatergic neurons, which serve as the primary excitatory cells of the human brain.[1]
Specifically, the pain-associated variants clustered heavily in the prefrontal cortex, the hippocampus, and the amygdala. These distinct regions form the cortico-limbic circuit, a complex neural network that governs not just the physical sensation of pain, but how that pain is remembered, anticipated, and emotionally processed by the patient.[1]
Sex Differences and Sample Disparities
Chronic pain is disproportionately prevalent among women, prompting the researchers to run sex-specific meta-analyses to look for divergent genetic drivers between male and female patients. The male-specific analysis identified 5,526 single nucleotide polymorphisms across 115 independent loci.[1]
In stark contrast, the female-specific analysis uncovered only 475 significant variants across 12 independent loci, initially suggesting a massive divergence in genetic architecture. However, the stark difference in identified loci does not necessarily mean that male pain is inherently more genetically complex.[1]
The male sample, drawn heavily from the military-focused Million Veteran Program, comprised 583,066 individuals, while the female cohort included only 241,266 participants. The authors attribute the massive gap in discovered loci primarily to this statistical power imbalance rather than underlying biology, emphasizing the urgent need for larger, sex-balanced genomic datasets.[1]
While the brain took center stage in the analysis, the study also highlighted specific peripheral targets where pain signals originate. In the dorsal root ganglia—the clusters of sensory neurons running alongside the spinal cord—the genetic risk was highly enriched in a specific subtype of C-fiber nociceptors.[1]
These specialized nerve fibers are responsible for detecting noxious heat and chemical stimuli. Confirming their foundational role in transmitting chronic pain signals from the body to the brain provides a concrete peripheral target for future drug development, complementing the central nervous system findings.[1]
Causal Links to Psychiatric Conditions
The genetic variants associated with chronic pain did not operate in isolation, revealing massive pleiotropy—a phenomenon where one gene influences multiple seemingly unrelated traits. The pain-linked variants overlapped heavily with the genetic architectures of insomnia, major depressive disorder, and post-traumatic stress disorder.[1][4]
This genetic overlap mirrors the clinical reality that these psychiatric conditions frequently co-occur in patients suffering from long-term pain. To determine whether these overlaps were merely correlational or genuinely causal, the team employed Mendelian randomization, a sophisticated analytical method that uses inherited genetic variants as natural experiments.[1]
By bypassing the confounding lifestyle variables that plague observational studies, the Mendelian randomization results provided robust statistical evidence. The analysis demonstrated that chronic pain causally contributes to the development of substance use disorders, rather than merely co-occurring with them.[1]
The analysis also linked the multidimensional pain variants to higher circulating levels of C-reactive protein. This specific protein is a widely used clinical biomarker of systemic inflammation, produced by the liver in response to tissue damage or active infection.[1]
Toward Objective Biomarkers
The causal link to C-reactive protein suggests that chronic pain is not just a localized neurological symptom, but a primary driver of broader inflammatory processes throughout the entire body. The researchers further cross-referenced their genetic findings with structural brain imaging data to look for physical manifestations of the risk variants.[1]
The multidimensional pain variants showed significant pleiotropic associations with several brain imaging-derived phenotypes, particularly those measuring the surface area and volume of specific cortical regions. This aligns with long-standing neuroimaging research showing that the transition from acute to chronic pain is accompanied by physical, structural remodeling in the brain.[1]
Despite its unprecedented scale and statistical power, the study carries a significant limitation: all 1,235,695 participants included in the final analysis were of European ancestry. The authors explicitly note that this genetic homogeneity restricts how accurately the findings can be applied to other global populations.[1]
The authors caution that identifying these 343 loci does not immediately point to a new analgesic drug or a rapid clinical cure. Instead, they offer the comprehensive results as the necessary groundwork for developing objective biomarkers and polygenic risk prediction models.[1]
By pinpointing the exact central and peripheral cell types that carry the genetic signatures of chronic pain, the study provides a precise, multi-omic roadmap. This foundational architecture will guide future targeted translational research, moving the medical field closer to objectively measuring and treating chronic pain.[1][2]
Key points
- A meta-analysis of three major biobanks identified 343 genetic loci linked to chronic pain, including 92 previously unknown sites.
- The research prioritized 490 genes associated with pain through their regulatory effects in brain and blood tissue.
- Sex-specific analyses revealed 115 genetic loci in males and 12 in females, though researchers attribute the gap largely to sample size differences.
- Mendelian randomization demonstrated causal links between pain variants and psychiatric conditions, substance use disorders, and elevated C-reactive protein.
Open questions
- How these genetic risk factors manifest in populations of non-European ancestry.
- Which specific biological mechanisms translate these genetic variants into the physical sensation of pain.
- When these genetic insights might yield clinically available biomarkers or targeted analgesic drugs.
- Genomic Researchers
- Emphasize that mapping the genetic architecture of chronic pain provides a foundational step toward developing objective biomarkers.
- Clinical Practitioners
- View the findings as a crucial step in understanding why chronic pain frequently overlaps with psychiatric conditions and substance use disorders.
- Biobank Curators
- Highlight the necessity of large, diverse, and sex-balanced datasets to accurately capture the genetic nuances of complex traits.
Perspectives this story doesn't cover
- Patients of non-European ancestry whose genetic risk profiles remain unmapped
- Chronic pain patients seeking immediate clinical treatments rather than long-term biomarker research
Sources
[1]Nature NeuroscienceGenomic ResearchersGene discovery and pleiotropic architecture of multidimensional pain in a genome-wide association study of >1.2 million individuals
Read on Nature Neuroscience →
[2]ScienmagClinical PractitionersGenome Study of 1.2 Million People Reveals 343 Pain Risk Loci
Read on Scienmag →
[3]Bioengineer.orgBiobank CuratorsGenome Study of 1.2 Million People Reveals 343 Pain Risk Loci
Read on Bioengineer.org →
[4]JClubGenomic ResearchersGene discovery and pleiotropic architecture of multidimensional pain in a genome-wide association study of >1.2 million individuals
Read on JClub →
More in Science
See all →Metabolic Therapies
Retatrutide Trial Shows GLP-1 Receptor Agonist Relieves Severe Osteoarthritis Pain
6 sources
Neuroimmunology
Brain Waste Drainage Failure and Protein Build-Up Drive Parkinson's Vicious Cycle
5 sources
Gene Therapy
First Human Trial of Chemogenetic Gene Therapy Cuts Epileptic Seizures by 92 Percent
5 sources
Drug Discovery
High-Throughput DNA Nanoswitches Accelerate Drug Discovery by Tracking Protein Interactions
6 sources
Comments
Every angle. Every day.
Get Science stories with full source coverage and perspective breakdowns, free every day.



